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Background: High level resistance to carbapenem antibiotics in gram 
negative bacteria such as Bacteroides fragilis is caused, in part, by 
expression of a wide-spectrum metallo-&lactamase that hydrolyzes the drug 
to an inactive form. Co-administration of metallo-5-lactamase inhibitors to 
resistant bacteria is expected to restore the antibacterial activity of 
carbapenems. 
Results: Biphenyl tetrazoles (BPTs) are a structural class of potent 
competitive inhibitors of metallo-p-lactamase identified through screening and 
predicted using molecular modeling of the enzyme structure. The X-ray crystal 
structure of the enzyme bound to the BPT L-l 59,061 shows that the tetrazole 
moiety of the inhibitor interacts directly with one of the two zinc atoms in the 
active site, replacing a metal-bound water molecule. Inhibition of metallo-p- 
lactamase by BPTs in vitro correlates well with antibiotic sensitization of 
resistant B. fragilis. 
Conclusions: BPT inhibitors can sensitize a resistant B. fragilis clinical isolate 
expressing metalloj34actamase to the antibiotics imipenem or penicillin G but 
not to rifampicin. 
Addresses: ‘Department of Biochemistry and 
2Department of Basic Chemistry, Merck Research 
Laboratories, P. 0. Box 2000, Rahway, 
NJ 07065-0900, USA. 
Correspondence: Jeffrey H Toney and 
David L Pompliano 
E-mail: jefftoney@merck.com and 
david-pompliano@merck.com 
Key words: antibiotic resistance, biphenyl 
tetrazoles, crystal structure, enzyme inhibitors, 
metallo-j3-lactamase 
Received: 10 November 1997 
Revisions requested: 5 December 1997 
Revisions received: 17 February 1998 
Accepted: 23 February 1998 
Published: 8 April 1998 
Chemistry & Biology April 1998, 5:185-l 96 
http://biomednet.com/elecref/1074552100500185 
0 Current Biology Ltd ISSN 1074-5521 
Introduction 
Carbapenem antibiotics such as imipenem (Primaxin@) 
have proven to be useful for the treatment of a variety of 
gram negative and gram positive infections [l-3]. At the 
molecular level, carbapenems and other p-lactam antibi- 
otics function by covalently modifying peptidoglycan 
biosynthetic enzymes responsible for catalyzing the final 
transpeptidation step of cell wall biosynthesis [4]. Inactiva- 
tion of these ‘penicillin-binding proteins’ by carbapenem 
antibiotics leads to cell lysis [S]. Carbapenems are gener- 
ally not hydrolyzed by class A serine-based p-lactamases 
[6] but are hydrolyzed rapidly by class B metallo-glacta- 
mases (Figure 1) [7] and are thus rendered ineffective. 
Species of Bacteroides, including Bactemides fragilis, are 
commonly found in clinical isolates from suppurative/surgi- 
cal infections [8]. Treatment options for B. fragiilis infec- 
tions typically include P-lactam/carbapenem agents such as 
amoxicillin and imipenem. A potentially major medical 
concern is that bacteria may develop resistance to car- 
bapenems in a similar manner to the widespread resistance 
currently observed for other p-lactam antibiotics. Antibiotic 
resistance mediated by class B p-lactamases is already 
emerging among Bacteroides species [9]. Simultaneous 
resistance to metronidazole, co-amoxiclav (see below) and 
imipenem in a B. fragilis clinical isolate was reported 
recently [IO] and was found to be due to an induced 
expression of a metallo-P-lactamase-like enzyme. 
One strategy for overcoming bacterial resistance to antibi- 
otics is to use combination therapy. Such a strategy has 
proven successful in combating resistance mediated by 
class A serine-based p-lactamases, for instance in treating 
bacterial infections normally resistant to agents such as 
amoxicillin. Co-amoxiclav (AugmentinTM) is comprised of 
the p-lactam antibiotic amoxicillin and clavulanic acid, a 
‘suicide’ inhibitor of the class A p-lactamases [ll]. Aug- 
mentinTM is effective in treating p-lactamase-producing 
strains of staphylococci, Hemophihs inf/zcenza, gonococci 
and Escher-i&a co/i. Our interest has been to identify 
potent inhibitors of class B P-lactamases that may be 
useful in combination with carbapenem antibiotics against 
resistant bacterial strains. 
Several genes encoding carbapenem and cephamycin resis- 
tance (ccrA) have been identified from independent iso- 
lates of B. fragdis [7] including the genes encoding the 
metallo-P-lactamases CcrA, CcrA3 and CcrA4. The three 
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Figure 1 
I 1 The hydrolysis reaction of imipenem by 
metallo-5-lactamase. 
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encoded enzymes differ by four amino acids out of a total 
of 249 residues. The enzyme described here differs from 
CcrA by having threonine instead of alanine at residue 171 
and asparagine instead of aspartate at residue 208. The 
crystal structure of the CcrA3 metallo-B-lactamase has 
been reported and reveals that the active site of the 
enzyme contains a binuclear zinc core [12]. The structure 
of metallo-B-lactamase from Bacillus ce~e2cs revealed a novel 
protein fold and one zinc atom in the active site [13], but 
more recent structural studies of the same enzyme reveal 
two zinc atoms in the active site (PDB entry 1BME). In 
the case of the CcrA sub-family of metallo-B-lactamases, 
the protein ligands of one of the zinc atoms, designated Zn 
1, are three histidine residues whereas the ligands for Zn 2 
are a histidine, an aspartic acid and a cysteine. In addition, 
the two zinc atoms are bridged by a water/hydroxide mol- 
ecule, resulting in a tetrahedral geometry for Zn 1 and a 
trigonal bipyramidal geometry for Zn 2, which is axially 
coordinated to an additional water molecule. The catalytic 
mechanism of hydrolysis has been proposed to involve the 
bridging water/hydroxide between the two zinc atoms in 
the active site that can serve as the attacking nucleophile 
on the carbonyl carbon of the B-lactam (Figure Za) [12]. In 
addition, both zinc atoms are thought to be required for full 
Figure 2 
catalytic activity [14]. Further experiments will be neces- 
sary, however, to determine whether the attacking nucle- 
ophile is the bridging water/hydroxide or a water molecule 
bound at the axial position on Zn 1 (Figure 2b) after dis- 
placement of the bridging water/hydroxide by substrate. 
Knowledge of the enzyme structure can provide insight 
into possible mechanisms of inhibition. As one may be 
able to predict and/or design molecules that can interact 
specifically with one or both of the zinc sites in the 
enzyme, compounds that selectively prevent substrate 
binding while not interfering with cellular zinc metabo- 
lism should be specific for metallo-B-lactamase. In con- 
trast, compounds with high affinity for hydrated zinc (e.g., 
PXH20),12+ [15,161) are expected to inhibit most Zn*+- 
dependent enzymes for which the metal is accessible by a 
chelator and would not be of therapeutic interest. 
The search for inhibitors of metallo-B-lactamase described 
in the present report employs screening techniques as well 
as use of the crystal structure of the enzyme for molecular 
docking of candidate inhibitors. These approaches have 
led to the identification of biphenyl tetrazoles (BPTs) as 
potent competitive inhibitors. This class of compounds 
Two of the possible mechanisms for the 
hydrolysis of a carbapenem. In (a) the substrate 
binds with the p-lactam carbonyl oxygen 
interacting with Zn 1. The attacking nucleophile 
is the hydroxide ion bridging Zn 1 and Zn 2. 
The interaction between the carbonyl oxygen 
and Zn 1 draws electron density away from the 
carbonyl carbon making it more electrophilic, 
thereby facilitating nucleophilic addition of the 
hydroxide ion. Zn 1 and possibly Zn 2 would 
(~~~Q;*o (b) H)$++/p 
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that described in (a). 
does not significantly affect mammalian dehydropeptidase 
I (DHP-I) [17,18], a metalloenzyme that is also capable of 
hydrolyzing imipenem [19] in addition to dehydropeptide 
substrates. Importantly, the inhibition of the purified 
recombinant metallo-B-lactamase by the BPT class of 
compounds is found to correlate well with the ability of 
the compounds to sensitize a B. fragdis imipenem-resistant 
clinical isolate to imipenem. 
Results 
Structure-activity relationships of biphenyl tetrazole 
metallo-&lactamase inhibitors 
Screening of the Merck chemical collection using nitro- 
cefin, a chromogenic cephalosporin, revealed a series of 
BPTs linked to various heterocyclic aromatic rings as 
inhibitors of metallo-B-lactamase. The unsubstituted BPT 
L-809,022 (R = H, Table 1) was found to to be a poor 
inhibitor with an IC,, value of 860f60pM and no 
detectable inhibition of DHP-I up to 1 mM. The ortho 
position of the tetrazole group relative to the biphenyl ring 
system was found to be important for enzyme inhibition 
because movement of the tetrazole group to the meta or 
para positions resulted in IC,, values of 10-20 mM. Sub- 
stitution of carboxamide for the tetrazole group at the 
ortho position also led to a loss of activity (IC,, > 20 mM). 
Similarly, movement of the carboxamide group to the 
meta or para positions led to a loss of activity with IC,, 
values of > 2.5 and > 1.0 mM, respectively. 
Inhibition of metallo-B-lactamase was increased signifi- 
cantly upon substitution at the 4’-position of the BPT. The 
parent compound L-158,507 (R = CH,, Table 1) had an 
IC,, of 160 pM, a fivefold greater activity than L-809,022. 
Substitution at this benzylic position with various hetero- 
cyclic aromatic groups led to even further increases in activ- 
ity. For example, addition of a benzimidazolyl fragment 
(L-808509) resulted in a moderate increase in inhibition 
(IC,, = 110 pM), and incorporation of Z-methylbenzimida- 
zole (L-809,559) led to a 40-fold increase in activity over the 
parent compound. The imidazo[4,5b]pyridinyl group 
(L-809,558) was found to be slightly more inhibitory than 
the benzimidazolyl fragment. Elaboration of the 
imidazo[4$b]pyridinyl group with a propyl group at posi- 
tion 2 and a chlorine at position 5 (L-158,678) led to a 
potent compound having -50-fold greater inhibition than 
the parent BPT. This inhibition could be increased further 
by substitution of a 7-methyl-Z-(Z-propyl)imidazopyridine 
(L-158,817). Interestingly, substitution of Z-butyl-6-hydrox- 
ylquinazolinone (L-159,061) led to a compound having 
-lOO-fold greater inhibition than the parent BPT. As a 
whole, these BPTs with heterocyclic aromatic substitution 
showed little or no activity against DHP-I. 
Metallo-B-lactamase inhibitors distinct from the benz- 
imidazolyl or imidazopyridyl class were also identified 
with little or no activity against DHP-I. An oxygen-linked 
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Table 1 
Enzyme inhibition by BPTs. 
3 
PdNH4 
1 
& 
,/\ /\ 
Compound 
L-809,022 
L-l 58,507 
L-808,509 
L-809,559 
L-809,558 
L-l 58,678 
L-158,81 7 
L-159,061 
L-809,339 
L-809,370 
L-161,189 
L-l 59,906 
L-707,581 
Metallo+ 
R lactamase DHP-I 
H 880 f60 
CH3 160 +20 
cd 110 f9 
a; 4+1 
b 
N 
c&J 
42 f10 
c&G 3.5 + 0.4 
ir 
R 1.8 + 0.4 
% 
42 f7 
6fl 
0.30 * 0.02 
0.4 + 0.1 
753 
>lOOO 
>lOOO 
so0 
>250 
>250 
240 +12 
>lOO 
>lOO 
>lOO 
>lOO 
120 zk 10 
>lOO 
190 f8 
2-hydroxycarbazolyl group (L-809,339) was found to be 
equipotent to the unsubstituted imidazopyridyl compound 
L-809,558. Linking the Z-hydroxycarbazole via the nitrogen 
rather than the oxygen (L-809,370) significantly increased 
the inhibition, whereas removal of the Z-hydroxyl moiety 
led to a very potent inhibitor, L-161,189, that had -500-fold 
greater activity than the parent BPT. 
Potent inhibitors were also identified belonging to the 
BPT class containing Z-butyl-thieno[3,2-dJpyrimidin+one 
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(L-159,906) or 4-ethyl-Z-propyl-imidazole-5-carboxaldehyde 
(L-707,581). Neither of these compounds inhibited DHP-I. 
Three examples of the most potent inhibitors identified in 
the screen, L-158,678, L-159,906 and L-159,061 were 
studied in greater detail. These compounds were found to 
have simple competitive kinetics with the substrate nitro- 
cefin, having K, values of 1.5 + 0.1 PM, 0.59 + 0.03 pM and 
1.6 f 0.4 pM (Figure 3a-c), respectively. No time-depen- 
dent inhibition of metallo-&lactamase by these compounds 
was observed under the same conditions employed to study 
enzyme inactivation (see below). To test for binding to 
metal ions, enzyme inhibition was measured after pre-incu- 
bation of the inhibitors with 100 p.M ZnC12. IC,, values of 
these compounds were unaffected by pre-incubation with 
&Cl2 within the uncertainty of the measurements. 
In contrast, compounds such as bis(lH-tetrazol-S-yl)amine 
(L-295,819) that lack the biphenyl portion were found to 
be inactivators that inhibited the enzyme in a time-depen- 
dent fashion (Figure 4). The IC,, value for bis( W-tetrazol- 
S-yl)amine was altered significantly by ZnClz from 17 FM 
without pre-incubation to a value of 60 ~.LLM with pre-incu- 
bation, a result consistent with expected attributes of a 
metal chelator. Anslysis of the kinetic data for bis( 1H-tetra- 
zol-S-yl)amine yielded a rate constant for inactivation of 
kinact = 0.52 min-l and kiJKi = 8900 M-W. Interestingly, 
metal chelators such as l,lO-o-phenanthroline or tropolone 
were found to show time-dependent inhibition with 
similar rates of inactivation (kinact = 0.44 and 0.62 min-l, 
respectively). Thus, the rate-limiting step of inactivation 
could be dissociation of zinc from the enzyme active site. 
Molecular modeling of candidate enzyme inhibitors 
The determination of the X-ray crystal structure of the 
complex of metallo-glactamase bound to 4-morpholi- 
neethanesulfonic acid (MES) (Ki -23 mM) [ZO] allowed 
the opportunity to use a computational approach to search 
for inhibitors in parallel with the screening efforts used 
prior to the availability of a crystal structure of the enzyme 
bound to more potent inhibitors. A view of the enzyme 
active site complexed with MES is shown in Figure 5. The 
FLOG (flexible ligands oriented on a grid) [Zl-231 
approach can scan a database of potential ligands by 
docking a three-dimensional structure into a grid represen- 
tation of the active site and calculating an ‘energy’ or score 
for each docking. Grid-based energy evaluation is 
designed to circumvent the need to calculate all the pair- 
wise interactions between the ligand and protein by repre- 
senting the active site as an ‘interaction energy field’, 
sampled at uniformly spaced points in a three-dimensional 
grid [23-Z]. At each point the potential energy within the 
active site is calculated and stored for each atom type used 
in the ligands. The score of a docked ligand is simply the 
sum of interaction energies for each ligand atom, based on 
the stored energies of the nearest grid points. In this study, 
Figure 3 
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Biphenyl tetrazoles are competitive inhibitors of metallo-P-lactamase. 
Lineweaver-Burk plots consistent with competitive inhibition using the 
following BPTs: (a) L-l 58,878, (b) L-l 59,906 and (c) L-l 59,061. 
Data shown represent the average of two independent experiments. 
the grids were calculated using residues within 6 A of the 
MES molecule found in the active site of the enzyme. 
The observation of two zinc-bound water molecules/ 
hydroxide groups suggested that several inhibitor-binding 
modes involving the metal centers might be possible. 
Consequently, several representations of the active site 
were used in grid and docking calculations and included 
Figure 4 
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Figure 5 
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Time (s) Chemistry K Biology 
Time-dependent enzyme inhibition by bis(1 H-tetrazol-5-yl)amine 
(L-295,81 9). Data shown are from a single representative experiment. 
the combinations of waters and essential match centers 
shown in Figure 6. In each case -1.6 x lo6 conformers 
were docked, and the best 100-500 scoring compounds 
from each calculation were chosen for measuring enzyme 
inhibition. Some compounds were predicted in more than 
one search, such that the following summaries describe 
only compounds not tested previously in the enzyme 
assay. The three searches yielded a total of 71 compounds 
that had IC,, values of < 20 PM, of which 56 were BPTs 
and 15 were compounds comprised of diverse classes 
referred to as non-BPTs. The compounds identified by 
the searches included the most potent BPTs containing 
heterocyclic aromatic groups identified concurrently in the 
screen for inhibitors. The active-site representation that 
included a bridging water/hydroxide and an essential 
match point at the position of the axial water bound to Zn 
2 (Figure 6, representation iii) yielded 52 compounds with 
IC,, values of I 20 pM out of a total of 427 tested samples 
and included 41 BPTs. Despite the finding that the non- 
BPTs identified in these calculations appeared to be 
potent metallo-B-lactamase inhibitors, most of these com- 
pounds were found either to bind to ZnCla in the absence 
of enzyme or to act as enzyme inactivators (e.g., 
L-295,819). These inhibitors were therefore not chosen 
for subsequent biological studies. 
Representation (iii) shown in Figure 6 was the most pre- 
dictive, accounting for all but four of the inhibitors identi- 
fied in these calculations. This suggested that the BPTs 
A view of the enzyme active site complexed with MES at 1.85 a 
resolution. See 1201 for structural details. 
could bind with the tetrazole replacing the axial water as a 
ligand to Zn 2, placing the biphenyl group in contact with 
a hydrophobic region of a flexible B strand composed of 
residues 27-35 extending above the enzyme active site. 
Two orientations of BPTs in the active site were observed 
for this binding mode, shown in Figure 7. The orientation 
shown in Figure 7a was observed more frequently than 
that shown in Figure 7b, although each binding mode 
yielded similar scores. 
Crystallography of metallo-blactamase bound to 
L-159,061: overall structure 
As L-159,061 was found to be a potent competitive 
inhibitor, it was chosen for crystallographic studies to 
define the mode of BPT binding. An overview of the 
structure of the enzyme-inhibitor complex is shown in 
Figure 8. The enzyme consists of two domains, each of 
which contains a B sheet lined on one face by a helices. 
The two domains have similar topology [13], but the 
amino-terminal domain contains a feature not present in 
the carboxy-terminal domain: a B strand formed by 
residues 27-35. We refer to the B strand (residues 27-35) 
as the flap of the enzyme, as it exhibits marked plasticity 
in the structures of the metallo-B-lactamases determined 
to date [l&13,20] (PDB entry 1BME). The active site is 
situated at the interface between the two B sheets and the 
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Figure 6 
3) 
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one bridging -OH former axial Ha0 
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Representation of the enzyme active site 
employed for molecular modeling. Three 
different configurations (i-iii) of the active-site 
waters and essential match points were used 
in computational searches for candidate 
inhibitors. The left hand column describes 
which water or hydroxide molecules were 
included in each case. The right hand column 
describes the location of the essential match 
point in the search. The positions of the 
active-site waters observed in the X-ray crystal 
structure with MES are labeled and color 
coded as follows: A, axial water (blue) on 
Zn 2; B, hydroxide ion (red) bridging Zn 1 and 
Zn 2; C, secondary water (green) hydrogen 
bonded to the bridging hydroxide ion between 
the two zinc atoms. 
BPT inhibitors bind in the cavity that is bounded by the 
active site and capped by the flap (Figure 8). 
The organization of the binuclear zinc cluster in the inhib- 
ited complex is similar to that observed for the unliganded 
B. fragifis enzyme [12] and for the complex with MES 
[ZO]. A well-defined water molecule bridges the two zinc 
atoms in the unliganded enzyme structure and the MES 0 
complex, which are both refined to 1.85 A, but there is no 
clear electron density at the position of the zinc-bridging 
Fiaure 7 
water molecule in the enzyme complex with L-159,061. At 
the resolution of the present crystal structure (2.55 A, 
Tables ‘2 and 3), we cannot be certain of its presence or 
absence. Interestingly, a recent report of the crystal struc- 
ture of the unliganded enzyme (2.0 A resolution) indicates 
the absence of a water molecule bridging the two zinc 
atoms [26]. The coordination of 22-r 2 is trigonal bipyrami- 
da1 in the unliganded enzyme structure and the complex 
with MES in which the axial ligand was a water molecule. 
In the structure of the enzyme-L-159,061 complex, the 
Chemistry & Biology 
The two orientations for BPT binding 
predicted by molecular modeling using the 
FLOG algorithm. Both (a) and (b) involve the 
tetrazole (blue) replacing a water (red) on 
Zn 2 as a ligand, and an interaction between 
the biphenyl group and the hydrophobic 
sidechains of the flap. The position of the 
water (red) replaced by the tetrazole is shown 
for the purpose of illustration. 
Figure 8 
The X-ray crystal structure of L-l 59,061 bound in the active site of 
6. fragilis metallo-a-lactamase. (a) A ribbon diagram of the overall 
complex at 2.55 A resolution. The two zinc atoms are shown as purple 
spheres, and the inhibitor is shown as a ball and stick model. The 
interaction between the inhibitor and Zn 2 is indicated by a red dashed 
line. (b) A view of the active site. The sidechain carbons and ribbon 
tracing of the a carbons are colored gray; nitrogens, oxygens and 
sulfur are purple, red and yellow, respectively. In the inhibitor, carbon, 
nitrogen and oxygen are green, purple and red, respectively. 
Interactions with the zinc are shown by black lines. 
axial position is occupied by the Nl atom of the tetrazole 
moiety of the inhibitor. The N3 atom of the tetrazole ring 
interacts with a solvent atom that in turn interacts with the 
terminal nitrogen atom of the sidechain of LysA167, 
although the solvent atom is not well defined at the resolu- 
tion of this structure. The N4 atom interacts with the 
amide nitrogen of AsnAl776. The biphenyl portion of the 
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Table 2 
Data collection statistics. 
Resolution Number of Mean 
range (A) reflections* Completeness Y/o(Y)+ R * merge 
w-4.63 .2601 0.940 31.6 0.042 
4.63-3.68 2462 0.875 13.1 0.070 
3.68-3.21 2217 0.795 6.7 0.102 
3.21-2.92 1960 0.716 4.1 0.125 
2.92-2.71 1691 0.613 2.9 0.123 
2.71-2.55 1468 0.530 2.4 0.125 
m-2.55 12599 0.750 12.1 0.077 
“The number of reflections with I > o(l). +Y = average of all observations 
of a given reflection. *Rmerge = C,,, Zi 1 I(hkl,i)-<l(hkl)> I/Z&, Xi ) I(hkl,i) 1 
inhibitor interacts with hydrophobic sidechains in the 
protein, principally provided by residues in the flap. The 
major enzyme-inhibitor interaction is observed between 
the second phenyl ring of the inhibitor and the sidechain of 
TrpA32, but there are also significant contacts with the 
sidechains of IleA and ValA35. The 6-hydroxyl position 
of L-159,061 interacts with @l of AspA and more 
weakly with Ns2 of AsnA208. A second polar interaction 
involves the oxygen of the quinazolinone group and the 
water molecule that bridges the interaction between N3 of 
the tetrazole ring and the terminal nitrogen atom of the 
sidechain of LysA167. The remaining interactions with the 
protein are hydrophobic, involving the second phenyl group 
of the inhibitor, the butyl substituent of the quinazolinone, 
and the sidechains of TrpA32, ValA34 and ProA36. Further 
details of the structure of the enzyme-inhibitor complex of 
L-159,061 and related BPTs will be presented elsewhere 
(P.M.D.F., N.G.-S., S.H.O., J.K.W. and J.H.T., unpub- 
lished observations). Taken together, the crystallographic 
data are consistent with the binding mode shown in 
Figure 7b predicted by the FLOG algorithm. 
Biological activity of biphenyl tetrazoles 
To test the hypothesis of whether inhibition of metallo- 
P-lactamase expressed in imipenem-resistant B. fragih 
would lead to sensitization of the cells to carbapenem or 
p-lactam antibiotics, a whole-cell agar diffusion assay was 
developed (see the Materials and methods section). Agar 
plates were prepared using an overnight culture of B. frag- 
il& CLA 355 grown under anaerobic conditions and then 
diluted in the presence of a sub-inhibitory concentration of 
imipenem, penicillin G or rifampicin at l/8 x the minimal 
inhibitory concentration (MIC). Inhibitors or a dimethyl- 
sulfoxide (DMSO) vehicle control were then added to 
wells bored into the agar. Zones of inhibition were mea- 
sured after incubation overnight. Addition of selected 
BPTs that had been identified as inhibitors of metallo-p- 
lactamase with an IC,, value of less than -40 PM led to sig- 
nificant zones of inhibition when imipenem or penicillin G 
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Table 3 
Summary of refined model. 
Number of restraints 
Root mean sauare deviation 0 Value in model Total >2 0 >3 0 
From ideal bond distances 
Bond distances 
Angle distances 
Planar l-4 distances 
From ideal planarity (A) 
From ideal chirality (A31 
From permitted contact distances (A) 
Single torsion contacts 
Multiple torsion contacts 
Possible H-bonds 
From ideal torsion angles (“) 
Planar groups (0 or 180) 
Staggered,groups (k 80 or 180) 
Orthonormal groups (+ 90) 
0.020 0.018 3650 90 7 
0.030 0.043 4981 508 166 
0.040 0.045 1325 64 29 
0.020 0.014 613 3 0 
0.150 0.209 562 56 21 
0.500 0.261 1335 0 0 
0.500 0.333 1645 8 0 
0.500 0.301 249 1 0 
3.0 2.4 460 7 0 
15.0 24.7 590 98 47 
20.0 25.6 52 3 2 
Resolution range (A) Number of reflections R 
10.00-6.74 653 0.240 
6.74-5.43 841 0.218 
5.43-4.67 972 0.163 
4.67-4.15 1035 0.148 
4.15-3.78 1108 0.161 
3.78-3.49 1143 0.163 
3.49-3.26 1165 0.175 
3.26-3.07 1163 0.185 
3.07-2.91 1133 0.191 
2.91-2.78 1105 0.190 
2.78-2.66 1058 0.195 
2.66-2.55 952 0.188 
10.00-2.55 12328 0.181 
but not rifampicin were employed as potential antibiotics 
(Table 4 and Figure 9). Several of the BPTs had weak 
antibacterial activity against CLA 3.55. In addition to their 
own antibacterial activity, L-809,370 and L-161,189 were 
able to potentiate the effect of sub-lethal concentrations of 
imipenem against the B. fragdis strain. 
Discussion 
Some BPTs have been reported to be potent nonpeptide 
antagonists of the peptide angiotensin II (AH), an impor- 
tant biological target for the treatment of hypertensive dis- 
orders [27]. The mode of inhibition of these compounds 
with the AI1 receptor subtype AT, is proposed to involve a 
lysine-aromatic interaction via the tetrazole moiety of the 
BPT [28] and does not involve metal binding. In the 
present report, BPTs have been shown to be potent com- 
petitive inhibitors of metallo-P-lactamase using kinetic as 
well as structural studies. Crystallographic studies of 
L-159,061 show that the tetrazole moiety displaces an axial 
water molecule bound to the Zn 2 atom within the active 
site of the enzyme, and that the biphenyl moiety forms 
favorable interactions with the hydrophobic residues of the 
flap extending above the active site. Such a mode of inter- 
action is consistent with the observed kinetics of competi- 
tive inhibition of the enzyme in the presence of substrate. 
The interaction between the tetrazole moiety of the BPT 
class and the active-site Zn 2 is not sufficient to account for 
the observed potent enzyme inhibition. The unsubstituted 
BPT L-809,022 is a weak inhibitor of metallo-b-lactamase. 
Thus, additional substituents are necessary to provide the 
strong binding interactions observed with compounds such 
as L-159,061 and L-161,189. Indeed, the determination 
of the crystal structure of the enzyme complexed with 
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Table 4 
Effect of BFTs on susceptibility of 6. fmgih CIA 355 to sub-WC concentrations of antibiotics. 
Zone size (mm)* 
Compound 
L-161,189 
L-l 58,817 
L-l 58,678 
L-809,559 
L-809,370 
L-809,558 
L-809,339 
L-809,022 
DMSO Control 
No addition 
14 
NZ 
NZ 
NZ 
12 
NZ 
10 
NZ 
NZ 
+ imipenem + Penicillin G 
2 uglml 8 uglml 
32 24 
37 25 
29 ND 
29 17 
34 24 
14 NZ 
11 NZ 
NZ NZ 
NZ NZ 
+ Rifampicin 
0.03 ug/ml 
13 
NZ 
NZ 
NZ 
12 
NZ 
NZ 
NZ 
NZ 
IC,, (PM)+ 
0.30 * 0.02 
1.8 f 0.4 
3.5 + 0.4 
4*1 
6fl 
42flO 
42 f 7 
860 rl: 60 
*Zones of inhibition produced by the BPTs against CLA 355 with and without addition of sub-MIC concentrations of antibiotic. +Measured using 
recombinant 6. fragifis metallo-a-lactamase. NZ, no zone of inhibition detected; minimum detectable zone size is 7 mm. ND, not determined. 
L-159,061 revealed that Trp32 present in the flexible B 
strand extending above the active site interacts with the 
second phenyl ring of the inhibitor as well as additional 
contacts between the enzyme and the quinazolinone group 
of the inhibitor. A mutation at residue 32 could conceiv- 
ably lead to resistance to BPT inhibitors. It is noteworthy 
that a tryptophan at residue 32 or the equivalent position is 
conserved in metallo-&lactamases found in the CcrA 
family and in IMP-l, a plasmid-mediated metallo-fi-lacta- 
mase found in Pseudomonas aemginosa, Sewatia marcescens 
and in Mehiella pneumoniae [7], but is deleted from 
metallo+lactamases found in B. cereus, Aeromonas 
hydrophila and Stenotrophomonas maltophilia [ 71. In addition, 
the nature of the heterocyclic ring system (Table 1) has a 
dramatic effect on enzyme inhibition, consistent with the 
idea that specific interactions of this moiety with active- 
site residues are necessary for potent enzyme inhibition. In 
contrast, the interactions between the biphenyl portion of 
the inhibitor and the flap extending above the active site 
appear to be relatively nonspecific. 
Knowledge of the structure of metallo-B-lactamase bound 
to MES allowed the use of molecular modeling techniques 
to complement the screening effort for enzyme inhibitors 
prior to the availability of a crystal structure of the enzyme 
bound to more potent inhibitors. An energy grid was gener- 
ated to represent the enzyme active site for docking of con- 
formers deposited in the Merck chemical database. The 
best 500 docking scores yielded 41 enzyme inhibitors 
belonging to the BPT class. An additional 15 inhibitors 
were identified in these searches that were distinct from the 
BPT class. The non-BPT inhibitors were found in general 
either to bind to ZnClz or to act as enzyme inactivators and 
thus were not studied further. Interestingly, none of the 
searches identified any compounds structurally related to a 
known substrate or the MES molecule in the original 
crystal structure [ZO]. The success of this docking technique 
demonstrates that prediction of enzyme inhibitors using 
algorithms such as FLOG can rapidly enhance the testing 
of available compounds by focusing on chemical classes that 
interact with the active site in a favorable manner. 
Inhibitors of metallo-B-lactamases belonging to chemical 
classes unrelated to BPTs have been reported. Mercapto- 
acetic acid thiol esters are irreversible inhibitors of metallo- 
B-lactamases from B. cereus, Stenotrophomonas mahophilia 
Figure 9 
(a) 
6. fragilis CIA 355 (b) B. fragilis CLA 355 + 
lmipenem 2pg/ml 
I A = DMSO B = L-809,022 
C=L-158,817 Chemistry 8 Biology 
Reversal of antibiotic resistance in a clinical isolate of B. fragilis by a 
BPT in synergy with imipenem. (a) Neither L-l 58,817 or L-809,022 
alone produces zones of inhibition against CLA 355. (b) In contrast, 
L-l 58,817 synergizes with imipenem, as shown by a zone of inhibition, 
whereas L-809,022, a weak metallo-/3-lactamase inhibitor, does not 
synergize with imipenem. DMSO is included as a solvent control. 
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and Aeromonas hydrophda but not from B. fragih [29]. Thiol 
esters have been shown to inhibit the B. cereus enzyme via 
hydrolytic release of mercaptoacetic acid which subse- 
quently covalently modifies a cysteine residue at the active 
site. That the B. fragihs enzyme is not significantly inhib- 
ited by the thiol esters suggests that the analogous active- 
site cysteine in this protein is less accessible to such 
inhibitors. Trifluoromethyl alcohol and ketone derivatives 
of L- or D-alanine have been reported to be competitive 
inhibitors of a metallo-P-lactamase from Xantlzomonas ma/- 
tophilia but not from B. cereus or Pseudomonas aeruginosa 
[30]. These compounds are proposed to bind to one of the 
Zn atoms in the active site as observed with the metalloen- 
zyme carboxypeptidase A [31]. To date, none of the classes 
of inhibitors described above including the BPTs (data not 
shown) show a broad spectrum of activity against all known 
metallo-P-lactamases, emphasizing the structural hetero- 
geneity of these enzymes. 
Studies using the metalloenzyme DHP-I reveal that the 
BPTs do not interact significantly with DHP-I. Both the 
absence of DHP-I inhibition and the lack of effect of 
ZnClz on the inhibition constants of metallo-p-lactamase 
argue against this class of compounds acting as nonspecific 
metal chelators. Taken together, these results indicate 
that the accessibility of compounds such as BPTs to the 
active site of metallo-P-lactamase and that of DHP-I are 
very different even though both enzymes are capable of 
hydrolyzing the same substrates. 
The biological activity of several representative BPTs 
against imipenem-resistant B. fragilis in synergy with 
imipenem or penicillin G highlights the potential use of 
such agents in the battle against resistant bacteria. Whole- 
cell activity was found to correlate well with inhibition data 
of purified metallo-P-lactamase (Table 4). One possible 
explanation for the observed biological activity is that the 
BPTs increase cell permeability to the antibiotic, but the 
BPTs did not sensitize imipenem-resistant B. fragic’is to 
rifampicin, an antibiotic that inhibits the initiation of RNA 
synthesis but not cell-wall biosynthesis, arguing against this 
possibility. Several of the BPTs were found to have small 
zones of inhibition in the absence of added antibiotic and 
this activity could be a result of the inhibition of cellular 
mechanisms other than inhibition of metallo-P-lactamases. 
In addition, two of the BPTs had small zones of inhibition 
in the presence of rifampicin but the size of these inhibition 
zones was similar to those (within experimental error) 
observed using the BPT in the absence of added antibiotic. 
Significance 
Drug resistance in bacteria is becoming an alarming 
problem worldwide and has been attributed, in part, to 
overuse of antibiotics [32] and to the expression of 
hydrolytic enzymes in bacteria that render antibiotics 
ineffective. One approach to the problem is to inhibit 
chemically a specific protein target that has been shown 
to play a major role in drug resistance such as the class 
B metallo-P-lactamases. Such inhibitors would not nec- 
essarily be expected to act as antibiotics in their own 
right but have the potential to increase the effectiveness 
of antibiotics already employed. Recently, the pheno- 
typic conversion of a drug-resistant bacterium to drug 
sensitivity has been accomplished genetically by a novel 
approach employing small oligoribonucleotides that 
cleave specifically the mRNAs encoding chlorampheni- 
co1 acetyl transferase or a serine-based p-lactamase [33]. 
The pharmacological and computational approach dis- 
cussed in the present report describes the phenotypic 
conversion of a resistant clinical strain through the use 
of metallo-P-lactamase inhibitors as a first step towards 
combating drug resistance in bacteria. 
Materials and methods 
Purified recombinant metallo@lactamase was prepared as described 
previously 1341 and differs from CcrA (Genbank accession number 
M63556) by having threonine instead of alanine at residue 171 and 
asparagine instead of aspartate at residue 208. 
Metal/o-/3-lactamase assays 
Metallo-P-lactamase activity was assessed using the chromogenic 
substrate nitrocefin [351. Enzyme preparations were diluted in 50 mM 
4-morpholinepropanesulfonic acid (MOPS), pH 7.0 in a 96 well 
microtiter plate. A tenfold concentrated stock of nitrocefin was pre- 
pared in 50% DMSO. Experiments employing a fixed substrate con- 
centration used nitrocefin at 20 pM (-K,) and enzyme at -5 nM. After 
incubating enzyme at 37°C for 15 m in the presence of inhibitor, reac- 
tions were initiated by addition of nitrocefin with a final volume of 
100 ul. Nitrocefin hydrolysis was monitored at 482 nm using a Mol- 
ecular Devices SpectraMax 250 microtiter plate reader. Reaction 
rates were linear from 3-5 min at 37°C. Stock solutions of inhibitors 
were typically prepared in 100% DMSO at 2-200 mM concentration. 
Enzyme activity was not significantly affected by addition of up to 20% 
DMSO (v/v). Initial velocities (vi) were measured and converted to o/, 
inhibition (%lNH) using %INH = l OO-(v,(with inhibitor)/q(without 
inhibitor))*lOO. IC,, values were calculated as the concentration of 
inhibitor at which 50% of the enzyme activity is inhibited using an in- 
house software package (Jim McGurk, MRL). Standard deviations 
reported for IC,, values represent between three and six independent 
determinations. Reported values for Ki were determined using a model 
for competitive inhibition: 
y = V,,‘xl /(xl + K,*(l + x2/K,)) 
where y = initial velocity of hydrolysis, xl = concentration of nitrocefin, 
x2 = concentration of inhibitor. 
Time-dependent inhibition was evaluated by fitting nonlinear progress 
curves to the first-order expression: y = a, (1 -e-u) where y is the con- 
centration of hydrolyzed product accumulated at each time point, a, is 
the total amount of product formed, k is the observed first-order rate 
constant, kobs , and t is assay time. Kinetic parameters for inactivation 
were determined using replots of half life t,,2 as a function of the recip- 
rocal of inhibitor concentration (36,371. SigmaPlot software (version 
4.14, Jandel Scientific) and MacNlin (in house software for nonlinear 
regression) were employed for fitting of data and error analysis. 
Renal dehydropeptidase I assays 
Reactions were carried out in 50 mM MOPS buffer, pH 7.1 using 10 pl 
purified porcine DHP-1 (5 pg/ml) at 37’C. After equilibration for 5 min, 
substrate glycyldehydrophenylalanine (K, -0.6 mM) was added to 
yield a final concentration of 50 pM. Rates of substrate hydrolysis were 
monitored for 15 min by measuring the decrease in absorbance at 
275 nm. Rates were fit to the equation: 
y = (a)(er-kt)) + c (2) 
where a = Az7snm of the substrate in the presence of inhibitor at time 
zero, c = final As7snm and k is the rate constant. Enzyme was isolated as 
described (381 with the modification that the renal cortex was homoge- 
nized using 20% butanol in 20 mM MOPS buffer, pH 7.1. 
Chemical synthesis of BPTs 
The BPT compounds described in this study were prepared using well- 
established procedures [39]. Bis(1 H-tetrazol-5-yl)amine (L-295,81 9) 
was obtained from Chembridge (Glenview, IL, USA). All other chemi- 
cals were of reagent grade. 
Crystallization and data collection 
A complex between L-159,061 and the metallo-5-lactamase from B. 
fragilis was crystallized in space group P2,2,2, by vapor diffusion 
equilibration against a solution containing 100 mM sodium cacodylate 
buffer, pH 6.8, 100 mM NaCI, 10 mM sodium acetate and 280/, (w/v) 
polyethylene glycol (PEG 4000). The cell constants were a = 71.36 A, 
b = 170.23 A and c = 40.68 A. A summary of data processing statis- 
tics is presented in Table 2. The structure was solved by the molecular 
replacement method [401, using the model of the‘enzyme complexed to 
MES as the probe structure [201. A model for the complex was refined 
using the program Prolsq [41] against data extending from 10.0 to 
2.55A in resolution. The R-factor for the final model was 0.181 and 
deviations from ideal bond distances were 0.018 A. R,,, was not moni- 
tored during refinement, although a cross-validation value of 0.306 was 
calculated for the final model. The quality and statistics of the refined 
model are summarized in Table 3. The coordinates have been 
deposited with the Protein Data Bank (entry code lA8T). Full details of 
the crystallographic analysis will be published elsewhere. Figures 5 and 
8 were created using the program Ribbons 1421. 
Molecular modeling 
Using the X-ray crystal structure of B. fragilis determined recently with 
MES bound in the active site 1201 the FLOG system for database 
searching and docking was used to identify enzyme inhibitors as 
described 121-231. Following the addition of polar hydrogens and 
assignment of hydrogen bonds and appropriate tautomeric states of 
imidszoles, the grids used to represent the active site were calculated 
with 0.3 A spacing, and included the entire residue of any atom within 
6 A of the MES molecule. In the formalism of the grid calculation, the 
zinc atoms are treated as a hydrogen-bond donor, without the angular 
term [21]. Consequently, favorable metal ligands will be hydrogen- 
bond acceptors. Neither formal charge nor metal-ligand bonds are con- 
sidered in this type of potential energy function. 
The grids and subsequent dockings were calculated including two, one 
or none of the waters observed in the X-ray crystal structure directly 
bound to a zinc ion. Neither the MES nor any other waters were 
included in the calculations. Match centers for docking ligands were 
generated at favorable interaction sites in the grid. The databases of 
three-dimensional structures or flexibases [231 contained typically 
between 5 and 25 conformatrons of each candidate inhibitor, using 
heavy atoms represented by 5 atom types (hydrogen bond donors, 
hydrogen bond acceptors, polar (both donor and acceptor), hydropho- 
bic and other) as previously described. 
Biological assays 
The imipenem-resistant Bacteroides fragilis clinical isolate, ClA 355, 
from which metallo-5-lactamase was cloned [341 was used in an agar dif- 
fusion model to evaluate enzyme inhibitors for their ability to increase the 
susceptibility of resistant bacteria to antibiotics. CLA 355 was grown 
overnight at 37’C under anaerobic conditions (AnaeroGen system from 
Oxoid) in Schaedler’s broth supplemented with vitamin K (Becton Dickin- 
son). Agar plates (20 ml in 100 mm petri dishes) were prepared using 
Wilkins-Chalgren agar (Difco) inoculated with a I:50 dilution of the 
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overnight 6. fragi/is culture containing imipenem at 2 pg/ml or penicillin 
G at 8 ug/ml (I 18 x MIC). An agar plate containing no antibiotic served 
as a control for assessing the antibacterial activity of inhibitors alone. A 
rifampicin-containing plate (0.03 kg/ml) served as a non-b-lactam control. 
A 2 mM solution of each inhibitor (2Oul) was placed into 7 mm wells in 
the agar and zones of inhibition were measured following overnight incu- 
bation at 37’C in an anaerobic environment. 
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